HLB Group

South Korea
Ulsan, Ulsan, South Korea, 216-53

Company profile

HLB Group company profile

HLB Group creates a management network to establish the conditions for the manufacture, sale, and discovery of new medications. They create rivoceranib, the cancer medicine, and "UNITE," a platform for the next generation of immunotherapy vaccines against cancer and allergies.

Business identity

Contact email
[email protected]
Phone number
82-52-240-3500
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
1985-01-01

Headquarters

Postal code
216-53
Country code
KR
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Articles
1
Exited on
1996-07-27

Founders and investors

No public relation records are available.